Study S000255

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT07868939
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 560
Start: 2026-10-16
Primary completion: 2028-10
Lead sponsor: Viking Therapeutics, Inc.
Conditions: Weight Loss
Interventions: DRUG:VK2735 Oral; DRUG:Placebo Comparator
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily [68 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.